Last reviewed · How we verify

Placebo of MCI-196

Tanabe Pharma Corporation · Phase 3 active Small molecule

Placebo of MCI-196 is a Small molecule drug developed by Tanabe Pharma Corporation. It is currently in Phase 3 development.

This is a placebo control arm and contains no active pharmaceutical ingredient.

At a glance

Generic namePlacebo of MCI-196
SponsorTanabe Pharma Corporation
ModalitySmall molecule
PhasePhase 3

Mechanism of action

As a placebo, this formulation is inert and produces no pharmacological effect. It is used as a control comparator in clinical trials to assess the efficacy and safety of the active drug MCI-196 relative to no treatment effect.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo of MCI-196

What is Placebo of MCI-196?

Placebo of MCI-196 is a Small molecule drug developed by Tanabe Pharma Corporation.

How does Placebo of MCI-196 work?

This is a placebo control arm and contains no active pharmaceutical ingredient.

Who makes Placebo of MCI-196?

Placebo of MCI-196 is developed by Tanabe Pharma Corporation (see full Tanabe Pharma Corporation pipeline at /company/tanabe-pharma-corporation).

What development phase is Placebo of MCI-196 in?

Placebo of MCI-196 is in Phase 3.

Related